Abstract
The aim of the study was to develop a method for assessing the risk of severity of the novel coronavirus infection COVID-19 in patients with chronic hepatitis C depending on the severity of liver fibrosis.Object and methods. The results of laboratory data of patients with COVID-19 and chronic hepatitis C (n = 147) were analyzed. According to the severity of liver fibrosis, patients with COVID-19 with chronic hepatitis C were divided into 3 subgroups: mild fibrosis (F1), moderate fibrosis (F2), severe fibrosis (F3). In blood serum, the parameters of total and biochemical (C-reactive protein, lactate dehydrogenase, alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transpeptidase, gamma-globulins, ferritin) blood tests, lipid profile (high-density lipoprotein cholesterol, triglycerides, apolipoprotein A1, apolipoprotein B), hemostasis (fibrinogen, activated partial thromboplastin time), cytokines (interleukin-2, tumor necrosis factor-а). All parameters were assessed in the acute period, depending on the severity of COVID-19 and the stage of liver fibrosis.Outcomes. Computer program for predicting the severity of COVID-19 in patients with chronic hepatitis C, depending on the stage of liver fibrosis, can be introduced into clinical practice for managing patients in the certain group.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have